Approval · Notice of Compliance 12218 · 2011
ACCEL-RISPERIDONE: Notice of Compliance 12218
Issued March 25, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12218
- Date
- March 25, 2011
- Company
- Accel Pharma IncPointe Claire, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Antipsychotic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACCEL-RISPERIDONE | 02365413 | — |
| ACCEL-RISPERIDONE | 02365421 | — |
| ACCEL-RISPERIDONE | 02365448 | — |
| ACCEL-RISPERIDONE | 02365456 | — |
| ACCEL-RISPERIDONE | 02365464 | — |
| ACCEL-RISPERIDONE | 02365472 | — |
Medicinal ingredients
- RISPERIDONE 0.25 MG per TAB
- RISPERIDONE 0.5 MG per TAB
- RISPERIDONE 1 MG per TAB
- RISPERIDONE 2 MG per TAB
- RISPERIDONE 3 MG per TAB
- RISPERIDONE 4 MG per TAB